Hepatic Encephalopathy Pipeline Summary

DelveInsight’s, “Hepatic Encephalopathy - Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Hepatic Encephalopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hepatic Encephalopathy: Understanding

Hepatic Encephalopathy: Overview

Hepatic encephalopathy (HE) is a neuropsychiatric condition arising from severe liver dysfunction, most commonly seen in patients with chronic liver disease and cirrhosis. The primary mechanism involves the liver's failure to detoxify blood-borne substances, particularly ammonia, which then accumulates and affects brain function. This condition manifests as a spectrum of neurocognitive impairments ranging from subtle cognitive deficits to profound confusion, stupor, and coma. The pathophysiology involves not only the direct toxic effects of accumulated substances but also neuroinflammation and altered neurotransmission.

Clinically, HE is categorized into various grades based on the severity of symptoms. In the early stages, patients may experience mild confusion, mood changes, and subtle motor disturbances such as asterixis (a flapping tremor of the hands). As the condition progresses, cognitive impairment becomes more pronounced, leading to lethargy, significant confusion, and eventually stupor or coma in severe cases. Diagnosis is primarily clinical, supported by laboratory tests showing elevated ammonia levels and liver function abnormalities, alongside neuropsychological testing and imaging to rule out other causes of altered mental status.

Treatment of HE focuses on reducing the production and absorption of ammonia in the gut. Lactulose, a non-absorbable disaccharide, is commonly used to acidify the colon and reduce ammonia levels. Rifaximin, an antibiotic, targets gut bacteria that produce ammonia. Dietary management, including protein restriction, may also be employed, though this approach is debated. Identifying and managing precipitating factors such as infections, gastrointestinal bleeding, and electrolyte imbalances are crucial. In cases of end-stage liver disease, liver transplantation remains the definitive treatment option, offering potential long-term relief.

The prognosis for HE largely depends on the severity of the underlying liver disease and the patient's response to treatment. Recurrent episodes are common, necessitating ongoing monitoring and management to prevent recurrence. Preventive measures include controlling the progression of liver diseases, regular monitoring for early signs of HE, and avoiding alcohol and hepatotoxic drugs.

"Hepatic Encephalopathy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic Encephalopathy pipeline landscape is provided which includes the disease overview and Hepatic Encephalopathy treatment guidelines. The assessment part of the report embraces, in depth Hepatic Encephalopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic Encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic Encephalopathy R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic Encephalopathy.

Hepatic Encephalopathy Emerging Drugs Chapters

This segment of the Hepatic Encephalopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatic Encephalopathy Emerging Drugs

• VE-303: Vedanta Biosciences

VE303, is a wholly-owned, orally-administered defined bacterial consortium candidate consisting of eight strains of live commensal bacteria for the prevention of rCDI. VE303 consists of a standardized and convenient oral pharmaceutical composition manufactured from pure clonal cell banks, with consistent quality attributes. The strains in VE303 have been selected for their ability to carry out multiple desired functions to prevent CDI recurrence, including: competition for growth substrates used by C. difficile and production of secondary bile acids, which are involved in C. difficile suppression, and short chain fatty acids (SCFAs), which are involved in gut barrier integrity and reducing inflammatory responses in the gut. Currently, VE303 is being evaluated in the Phase II trial for the treatment of Hepatic Encephalopathy.

• YAQ007: Yaqrit Discovery Ltd

YAQ007 also known as L-Ornithine Phenylacetate (L-OPA) has a unique mechanism of action involving its permanent excretion as phenylacetylglutamine (PAGN). YAQ007 is the oral formulation of L-ornithine phenylacetate (L-OPA), a potent ammonia-scavenging agent. Yaqrit is preparing to start a Phase IIb/III trial with YAQ007 for outpatient use to prevent recurrence of overt HE. Currently, YAQ007 is being evaluated in the Phase II trial for the treatment of Hepatic Encephalopathy.

• EBX-102: EnteroBiotix Limited

EBX 102 is a next-generation, full-spectrum microbiome therapy comprising a high-diversity microbial consortium, formulated as a stabilized, dried, off-white, odorless powder. It is designed to deliver rapid, well-tolerated, and effective management of conditions associated with the gut microbiome, including liver cirrhosis and hepatic encephalopathy. The product is administered orally and functions as a bacterial replacement and gastrointestinal microbiome modulator. Currently, the therapy is in Phase II stage of its development for the treatment of Hepatic Encephalopathy.

Further product details are provided in the report……..

Hepatic Encephalopathy: Therapeutic Assessment

This segment of the report provides insights about the different Hepatic Encephalopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hepatic Encephalopathy

There are approx. 8+ key companies which are developing the therapies Hepatic Encephalopathy. The companies which have their Hepatic Encephalopathy drug candidates in the most advanced stage, i.e. Phase II include, Vedanta Biosciences, and others.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Hepatic Encephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatic Encephalopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatic Encephalopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic Encephalopathy drugs.

Hepatic Encephalopathy Report Insights

• Hepatic Encephalopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatic Encephalopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatic Encephalopathy drugs?
• How many Hepatic Encephalopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatic Encephalopathy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatic Encephalopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatic Encephalopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vedanta Biosciences
• Yaqrit Discovery Ltd
• EnteroBiotix Limited

Key Products

• VE-303
• YAQ007
• EBX-102